Disease Diagnosis TRIZ Cases

Replacing mass spectrometry with sandwich ELISA improves diagnostic throughput while maintaining measurement precision for Alzheimer's disease detection.

Immunofluorescence assays quantify pan-cytokeratin and E-cadherin markers in tissue samples to distinguish progressive from nonprogressive colorectal cancer.

Glycosylated KIR4.1 peptides bind anti-KIR4.1 antibodies to distinguish multiple sclerosis from clinical isolated syndrome.

An immunoassay unit activates cells to release analytes for immediate detection without pre-treatment steps.

Analyzing biomarkers like GDF-15 and IL-6 targets statin treatment to responsive subgroups, reducing adverse effects and healthcare costs.

A diagnostic assay detects autoantibodies against hnRNP-DL polypeptides to identify autoimmune diseases.

Vaccine targets repetitive organellar proteins to overcome limited effectiveness and drug resistance in malaria control.

Combining pro-adrenomedullin levels with BODE-index parameters enables precise clinical monitoring.

Kindlin-1 expression measurement selects patients for EGFR inhibitor therapy, avoiding unnecessary treatments and side effects.

Diagnostic binding agents detect molecular targets to select patients for targeted prostate cancer therapy, preventing androgen-independent cell development.

GC/MS analysis of urinary adrenal steroid metabolites identifies distinct biochemical profiles.

Proteomic profiling detects glycosylated fibronectin and adiponectin levels, replacing invasive glucose tolerance tests with cost-effective screening.

A test strip detects human serum albumin in tear samples using immuno-chemical reactions to classify dry eye conditions accurately.

Quantifying urinary ADMA and SDMA levels enables accurate kidney function assessment, resolving the specificity limitations of serum creatinine tests.

A point-of-care test measures IP-10 and IL-1 levels in cervicovaginal fluid to detect asymptomatic bacterial vaginosis and sexually transmitted infections.

LRG1 protein markers detect recurrence risk via immunoassays, preventing overtreatment by identifying high-risk patients.

Detects Sjogren's disease via ELISA assays measuring autoantibodies to salivary gland protein 1, parotid secretory protein, and carbonic anhydrase 6.

Measuring serum neurofilament-light concentrations via ultrasensitive immunoassays identifies at-risk individuals before symptom onset.

Segmenting biomarker measurements into independent assays enables early AKI risk identification without increasing device complexity.

Segmented SWATH-MS windows and a pre-built citrullinated library resolve subtle mass shifts to quantify peptides accurately.

Identify NTNG1 autoantibodies via blood assays to diagnose membranous glomerulonephritis without invasive biopsies.

Antibodies targeting chorismate mutase proteins enable rapid differential diagnosis of Acanthamoeba keratitis, bypassing week-long culture procedures.

Urinary vitronectin protein levels replace invasive biopsy procedures to detect kidney fibrosis, enabling frequent monitoring without patient morbidity.

Segmented neoepitope binding resolves specificity issues, enabling precise osteoarthritis monitoring.

A lagomorph antibody immunoassay detects the ALT1 isoform mass concentration in blood samples using specific binding agents.

Detecting secreted frizzled related protein-4 in urine samples enables accurate polycystic kidney disease diagnosis.

Biochemical marker panels replace invasive procedures to reliably detect CNS endothelial injury for neurological disorder management.

A serum biomarker panel identifies glaucoma through specific protein expression levels.

Serum nitric oxide concentration measurement predicts atrial fibrillation and acute kidney injury without invasive tissue biopsies.

Blood GFAP measurements replace subjective clinical assessments to diagnose depression and PTSD, reducing misdiagnosis rates.

A lateral flow assay cassette integrates a vertical swab holder to secure the specimen head against the sample pad.

Combining antibodies against AMACR, CK5/6, and HMWCK resolves the contradiction between diagnostic accuracy and method complexity.

Measuring semaphorin 3A protein concentration in urine samples enables direct detection of urothelial cancer presence without invasive procedures.

Quantifying CD8+ and DC-LAMP+ cell densities in tumor tissue samples enables precise survival time prognosis for solid cancer patients.

Replacing conventional oligoclonal bands with Crtac1B protein measurement improves diagnostic specificity and sensitivity for multiple sclerosis.

Segmented nitrocellulose membranes enable simultaneous detection of multiple analytes, eliminating sequential testing bottlenecks in point-of-care diagnostics.

A variant TTR binding reagent forms stable complexes with monomers for precise quantification.

Confocal imaging of microtentacles on circulating tumor cells identifies metastatic risk and guides targeted therapy.

Analyzing saliva interferon gamma and interleukin-2 levels to detect degenerative joint disease in animals.

Flow cytometry detects drug antibodies using patient self-cells and fluorescent labeling to identify presence and affinity.

Segmented peptide-MHC complexes reduce toxicity to non-cancerous tissues while maintaining effective anti-tumor T cell activity across multiple malignancies.

Semi-quantitative pGOLD assay differentiates recent from remote infections by measuring antibody avidity patterns.